So that's an important time to keep under consideration. As most of us remember from CD-12, the DSMB can suggest a trial be discontinued either for SAEs/lack of efficacy OR for pronounced efficacy.in one of the two arms. In this case, one arm is 350 and one 700 mg. As I understand it, if 700 shows marked efficacy vs. 350, the DSMB can recommend that all patients receive 700.

Ohm, do you suspect that this might happen? I don't know if that change would have to be made public knowledge. Would it?

TIA.